UNSPSC 51142028: Phenacetin or phenacetinum

This classification denotes an organo-nitrogen carcinogen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ER0CTH01H9. European Medicines Agency schedules Phenacetin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09745MIG. Phenacetin generally arises in the molecular formula C10H13NO2.

The term PHENACETIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) PHENACETIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Phenacetin or phenacetinum bears US NLM identifiers UMLS ID C0031364 and NCI Concept Code C44432. SMILES: CCOC1=CC=C(C=C1)NC(=O)C.

UNSPSC 51142028 Phenacetin or phenacetinum is a Commodity code nominally describing a specific analgesic compound, but the recent state and local opportunities tagged under it diverge substantially from that scope. The three solicitations in the active pipeline reflect procurement of naloxone and drug deactivation systems, multi-source generic pharmaceuticals and OTC products through cooperative purchasing, and exploratory contracting for direct-to-manufacturer prescription programs. State and local buyers under this code—Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) on behalf of Minnesota and Oregon—show that the taxonomy assignment reflects neither phenacetin itself nor a unified pharmaceutical family, but rather pharmaceutical procurement across public health, HHS, and cooperative purchasing channels. The work being solicited ranges from tactical emergency-response supply acquisition (naloxone kits and drug deactivation systems for community health) through formulary-based generic pharmaceutical contracting to strategic market research supporting future direct-supplier relationships in state pharmacy benefit programs.

Recent activity is concentrated in the Southwest and Upper Midwest, with Seminole County's IFB for naloxone and safe drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, due July 26, 2023, delivered quarterly to Sanford, Florida) and the MMCAP RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, with contract effectiveness July 1, 2026, spanning Minnesota and Oregon) anchoring the pipeline. The Texas HHS Commission's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026) signals emerging interest in pharmacy supply chain restructuring and is exploratory rather than a binding commitment. The code shows no unified procurement pattern; the phenacetin designation appears to be a data-classification mismatch, and business development professionals should treat opportunities under this code as individually sourced rather than part of a coherent category. The Seminole County solicitation does not specify set-asides; the MMCAP contract does not identify disadvantaged-enterprise restrictions; and the Texas RFI remains in information-gathering phase with no formal timeline or budget parameters disclosed.